GAD-7 Explained: Measuring Anxiety in Primary Care
The GAD-7 is a seven-item questionnaire that measures the severity of anxiety symptoms over the past two weeks. Each item scores 0 to 3, for a total of 0 to 21. It is used in primary care to screen for anxiety and to track whether treatment is working over time.
Anxiety is one of the most common reasons people feel unwell, and much of it is treated — or missed — in primary care rather than a specialty clinic. The GAD-7 gives a clinician a fast, consistent way to put a number on something that is otherwise easy to under-report: how anxious a patient actually is, and whether that is changing.
The GAD-7 (Generalized Anxiety Disorder-7) is a validated, self-administered scale developed by Spitzer and colleagues in 2006. A patient rates how often, over the last two weeks, they have been bothered by seven problems — things like feeling nervous or on edge, not being able to stop or control worrying, trouble relaxing, and becoming easily annoyed or irritable.
Each item is answered on the same four-point scale:
It takes most patients a couple of minutes to complete, on paper or through a portal, which is part of why it fits a busy primary care visit. It is a screening and severity tool, not a diagnosis on its own.
Add the seven item responses for a total between 0 and 21. Higher scores mean more anxiety. The commonly cited severity bands are:
A score of 10 or higher is the usual threshold for a positive screen — the point at which a clinician looks more closely and considers further assessment. At that cutoff, the GAD-7 has been shown to identify generalized anxiety disorder with good sensitivity and specificity in validation studies. A shorter two-item version, the GAD-2 (the first two questions), is sometimes used as an even quicker first pass, with a positive GAD-2 prompting the full seven items.
An important caution: the score describes symptom severity, not a diagnosis. A high score signals that a clinical conversation is warranted; a diagnosis depends on that clinician's judgment, the patient's history, and ruling out other causes.
Screening means checking for a condition before — or independent of — a patient raising it. Many people never volunteer anxiety symptoms during a visit for something else, and clinicians can't reliably catch it by impression alone. A brief standardized tool given to patients routinely surfaces symptoms that would otherwise go unnoticed.
Beyond generalized anxiety, the GAD-7 also has reasonable sensitivity for other common anxiety conditions, including panic disorder, social anxiety disorder, and post-traumatic stress. That makes it a practical single instrument for a first look at anxiety in primary care, where visit time is short and the range of possible conditions is wide.
Screening finds the problem once. Measurement-based care uses the same tool repeatedly to guide treatment. The idea is simple: measure symptoms at the start, set a target, re-measure at regular intervals, and change the plan when the number isn't moving in the right direction.
The GAD-7 is well suited to this because it is short enough to repeat often and sensitive enough to detect change. A patient who scores 16 at baseline, 11 after a month, and 6 after three months is showing a clear response — and one who stays at 15 signals that the current approach needs to change, rather than waiting to find out at a distant follow-up. Tracking the trend turns a single snapshot into a feedback loop.
This is a meaningful shift from treating anxiety by impression, where "how are you feeling?" can mask a lack of real progress. A consistent score makes stalled treatment visible early.
The GAD-7 comes from the same family of tools as the PHQ-9, the nine-item questionnaire for depression, and the two are frequently used side by side. Depression and anxiety often occur together, and each can worsen the other, so measuring only one gives an incomplete picture.
The practical difference is what they measure:
Used as a pair, they let a primary care team see both dimensions of a patient's mental health on the same visit, track them independently, and tailor treatment to whichever is driving the distress. Many practices administer both routinely for exactly this reason.
The Collaborative Care Model (CoCM) is an evidence-based way of treating common mental health conditions inside primary care, backed by more than 90 randomized controlled trials. A behavioral health care manager works alongside the patient's primary care doctor and a consulting psychiatrist, and the whole approach is built on measurement.
In that model, the GAD-7 (usually alongside the PHQ-9) does specific work:
Because collaborative care manages a whole caseload rather than one visit at a time, repeated GAD-7 scores are how the team keeps track — the registry that tells them where each patient stands and who needs attention next. The tool doesn't replace clinical judgment; it focuses it.
A total of 0–4 is generally considered minimal anxiety. Scores of 5–9 indicate mild, 10–14 moderate, and 15–21 severe symptoms. A score of 10 or higher is the common threshold for a positive screen that warrants a closer look.
No. It measures the severity of anxiety symptoms over the past two weeks. A high score flags that further assessment is worthwhile, but only a clinician can make a diagnosis, taking history and other causes into account.
There is no single rule, but in measurement-based and collaborative care it is typically re-administered at regular intervals — often every few weeks early in treatment — so the team can see whether symptoms are improving and adjust the plan if they aren't.
The GAD-7 measures anxiety; the PHQ-9 measures depression. They come from the same family of tools and are often used together, because depression and anxiety frequently co-occur and each is tracked separately.
The patient does — it is a self-report questionnaire. That is part of its value: it captures the patient's own experience of their symptoms, on paper or through a portal, in just a couple of minutes.
